# Solitary fibrous tumor of the chest wall with Doege–Potter syndrome: a case report

**Authors:** Hongfei Zhang, Xinyue Weng, Yuqi Zhang, Yuchen Wang, Jiangyue Liu, Yutao Pang, Ang Li, Boyun Deng, Fasheng Li, Jie Chen, Zhu Liang, Zhan He, Dong Wu, Zhuming Chen

PMC · DOI: 10.3389/fonc.2025.1630793 · Frontiers in Oncology · 2026-01-07

## TL;DR

A rare case of chest wall tumor with a syndrome causing low blood sugar and potassium was successfully treated with a multidisciplinary approach.

## Contribution

A novel case report demonstrating the effective use of preoperative embolization and neoadjuvant therapy for a rare tumor syndrome.

## Key findings

- Preoperative vascular embolization reduced intraoperative blood loss to 200 mL.
- Neoadjuvant therapy achieved stable disease per RECIST 1.1 criteria.
- Postoperative metabolic abnormalities resolved with no recurrence observed during follow-up.

## Abstract

To describe the management of a rare chest wall solitary fibrous tumor (SFT) complicated by Doege–Potter syndrome (DPS), emphasizing the critical roles of multidisciplinary consultation and preoperative vascular embolization in optimizing outcomes.

A 56-year-old male presented with exertional dyspnea, dizziness, recurrent hypoglycemia, and hypokalemia. Contrast-enhanced computed tomography (CT) identified a large chest wall mass (19.2 × 13.3 × 21.6 cm), with biopsy confirming SFT. Multidisciplinary evaluation established a diagnosis of DPS. The patient underwent three cycles of neoadjuvant chemo-immunotherapy (albumin-bound paclitaxel, cisplatin, and anlotinib), followed by preoperative tumor vascular embolization. Surgical intervention involved en bloc tumor resection, left upper lobe wedge resection, and partial resection of the fifth rib.

Neoadjuvant therapy resulted in stable disease per RECIST 1.1 criteria. Preoperative embolization significantly reduced intraoperative blood loss to 200 mL, enabling an uneventful surgery. Postoperatively, hypoglycemia and hypokalemia resolved, and lung re-expansion was satisfactory. As of December 31, 2024, outpatient follow-up revealed no evidence of recurrence or metabolic abnormalities.

This case highlights the importance of recognizing DPS as a rare manifestation of chest wall SFT and underscores the value of multidisciplinary strategies in managing large tumors. Preoperative vascular embolization effectively minimized surgical risks and corrected metabolic disturbances, facilitating successful resection. Further studies are warranted to refine therapeutic approaches for this uncommon clinical entity.

## Linked entities

- **Chemicals:** cisplatin (PubChem CID 5460033), anlotinib (PubChem CID 25017411)
- **Diseases:** hypoglycemia (MONDO:0004946), hypokalemia (MONDO:0003019)

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** SFT (MESH:D054364), hypokalemia (MESH:D007008), dizziness (MESH:D004244), metabolic abnormalities (MESH:D008659), DPS (MESH:C536482), blood (MESH:D006402), dyspnea (MESH:D004417), hypoglycemia (MESH:D007003), tumor (MESH:D009369)
- **Chemicals:** cisplatin (MESH:D002945), anlotinib (MESH:C000625192), paclitaxel (MESH:D017239)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12819229/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12819229/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12819229/full.md

---
Source: https://tomesphere.com/paper/PMC12819229